Press releases
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
- Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
- Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
- Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
- Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
- RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
More ▼
Key statistics
As of last trade Lineage Cell Therapeutics Inc (BT3:DEU) traded at 1.36, -11.11% below its 52-week high of 1.53, set on Aug 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.26 |
---|---|
High | 1.36 |
Low | 1.26 |
Bid | 1.32 |
Offer | 1.34 |
Previous close | 1.37 |
Average volume | 536.00 |
---|---|
Shares outstanding | 188.53m |
Free float | 180.75m |
P/E (TTM) | -- |
Market cap | 263.95m USD |
EPS (TTM) | -0.1243 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 10:28 BST.
More ▼